KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Debt (2021 - 2026)

Pacira BioSciences has reported Non-Current Debt over the past 10 years, most recently at $367.7 million for Q1 2026.

  • For Q1 2026, Non-Current Debt rose 262.26% year-over-year to $367.7 million; the TTM value through Mar 2026 reached $367.7 million, up 262.26%, while the annual FY2025 figure was $372.2 million, 2.96% down from the prior year.
  • Non-Current Debt for Q1 2026 was $367.7 million at Pacira BioSciences, down from $372.2 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $383.5 million in Q4 2024 and troughed at $97.8 million in Q2 2025.
  • A 5-year average of $220.0 million and a median of $137.5 million in 2023 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: crashed 61.93% in 2023 and later surged 262.26% in 2026.
  • Year by year, Non-Current Debt stood at $251.1 million in 2022, then tumbled by 54.11% to $115.2 million in 2023, then skyrocketed by 232.93% to $383.5 million in 2024, then dropped by 2.96% to $372.2 million in 2025, then dropped by 1.22% to $367.7 million in 2026.
  • Business Quant data shows Non-Current Debt for PCRX at $367.7 million in Q1 2026, $372.2 million in Q4 2025, and $376.7 million in Q3 2025.